NCCN Guidelines® Insights

Featured Updates to the NCCN Guidelines

Richard L. Theriault, DO; Robert W. Carlson, MD; Craig Allred, MD; Benjamin O. Anderson, MD; Harold J. Burstein, MD, PhD; Stephen B. Edge, MD; William B. Farrar, MD; Andres Forero, MD; Sharon Hermes Giordano, MD, MPH; Lori J. Goldstein, MD; William J. Gradishar, MD; Daniel F. Hayes, MD; Clifford A. Hudis, MD; Steven J. Isakoff, MD, PhD; Britt-Marie E. Ljung, MD; David A. Mankoff, MD, PhD; P. Kelly Marcom, MD; Ingrid A. Mayer, MD; Beryl McCormick, MD; Lori J. Pierce, MD; Elizabeth C. Reed, MD; Lee S. Schwartzberg, MD, PhD; Mary Lou Smith, JD, MBA; Hatem Soliman, MD; George Somlo, MD; John H. Ward, MD; Antonio C. Wolff, MD; Richard Zellars, MD; Dorothy A. Shead, MS; and Rashmi Kumar, PhD

Abstract

These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer. (JNCCN 2013;11:753–761)

From 1The University of Texas MD Anderson Cancer Center; 2Stanford Cancer Institute; 3Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 4University of Washington/Seattle Cancer Care Alliance; 5Dana-Farber/Brigham and Women’s Cancer Center; 6Roswell Park Cancer Institute; 7The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 8University of Alabama at Birmingham Comprehensive Cancer Center; 9Fox Chase Cancer Center; 10Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 11University of Michigan Comprehensive Cancer Center; 12Memorial Sloan-Kettering Cancer Center; 13Massachusetts General Hospital Cancer Center; 14UCSF Helen Diller Family Comprehensive Cancer Center; 15Duke Cancer Institute; 16Vanderbilt-Ingram Cancer Center; 17UNMC Eppley Cancer Center at The Nebraska Medical Center; 18St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; 19Research Advocacy Network; 20Moffitt Cancer Center; 21City of Hope Comprehensive Cancer Center; 22Huntsman Cancer Institute at the University of Utah; 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and 24National Comprehensive Cancer Network.

Disclosures for the NCCN Breast Cancer Panel

Individual disclosures of potential conflicts of interest for the NCCN Breast Cancer Panel members can be found on page 754.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel’s discussion, including the literature reviewed.

The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines are available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
NCCN: Continuing Education

Accreditation Statement
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. There is no fee for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians. NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is accredited for 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

Disclosure of Affiliations and Significant Relationships: NCCN Breast Cancer Panel

The following authors have disclosed that they have financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products or devices discussed in this report or their competitors: Dr. Theriault, Dr. Allred, Dr. Burstein, Dr. Edge, Dr. Farrar, Dr. Giordano, Dr. Hudis, Dr. Mayer, Dr. McCormick, Dr. Ward, and Dr. Zellars.

The following authors have disclosed that they have financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products or devices discussed in this report or their competitors:

Dr. Somlo: PI for AstraZeneca Pharmaceuticals LP, Celgene Corporation, and National Cancer Institute. Advisor for Veridex, LLC.

Dr. Soliman: PI for Agendia BV. Speakers’ bureau member for Agendia BV, Celgene Corporation, and NanoString Technologies, Inc.

Dr. Schwartzberg: PI for Bristol-Myers Squibb Company. Advisory board member for Amgen Inc. Speakers’ bureau member for Eisai Inc.; Genentech, Inc. and Genomic Health, Inc. Data monitoring committee for Genentech, Inc. and Novartis Pharmaceuticals Corporation.

Dr. Mankoff: Research support from Merck & Co., Inc. and Pfizer Inc. Speakers’ bureau member for Genzyme Corporation.

Dr. Ljung: PI for National Cancer Institute.

Dr. Mankoff: Research support from Merck & Co., Inc. and Pfizer Inc. Speakers’ bureau member for Genzyme Corporation.

Dr. Marcom: Research support from Genentech, Inc. and Novartis Pharmaceuticals Corporation. PI for DoDiCDMRP. Speakers’ bureau member for Genentech, Inc.

Dr. Pierce: Advisory board member for Genomic Health, Inc.

Dr. Reed: PI for Novartis Pharmaceuticals Corporation. Advisory board member for UnitedHealthcare.

Dr. Schwartzberg: PI for Bristol-Myers Squibb Company. Advisory board member for Amgen Inc. Speakers’ bureau member for Eisai Inc.; Genentech, Inc. and GlaxoSmithKline.

Ms. Smith: Data safety monitoring board for Genentech, Inc. Advisory board member for AstraZeneca Pharmaceuticals LP. Board member for Gateway for Cancer Research Foundation and National Accreditation Program for Breast Centers.

Dr. Soliman: PI for Agenda BV. Speakers’ bureau member for Agenda BV, Celgene Corporation, and NanoString Technologies, Inc. Advisory board member for Veridex, LLC.

Dr. Somlo: PI for AstraZeneca Pharmaceuticals LP, Celgene Corporation, and National Cancer Institute. Advisor for Veridex, LLC. Advisory board member, consultant, and member of the speakers’ bureau for Genentech, Inc.; Abraxane; and Roche Laboratories, Inc. Advisory board member for Celgene Corporation; Millennium Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.

Dr. Wolff: PI for Bristol-Myers Squibb Company.

The NCCN Guidelines Staff have no conflicts to disclose.

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 70% minimum passing score and complete the evaluation at http://education.nccn.org/node/24674; and 4) view/print certificate.

Release date: July 12, 2013; Expiration date: July 12, 2014

Learning Objectives:
Upon completion of this activity, participants will be able to:

• Integrate into professional practice the updates to NCCN Guidelines for Breast Cancer
• Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer

EDITOR: Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE AUTHORS: Deborah J. Moonan, RN, BSN, Manager, CE Supporter Outreach, has disclosed the following relationships with commercial interests: AstraZeneca: Stockholder/Former Employee. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships. James Prazak, RPH, Assistant Director, Continuing Education and Grants, has disclosed the following relationships with commercial interests: Bristol-Myers Squibb Company; Pension; Pfizer, Inc: Stockholder; United Healthcare Group: Stockholder; Johnson & Johnson: Stockholder. Dorothy A. Shead, MS, Director, Patient and Clinical Information Operations, has disclosed no relevant financial relationships. Rashmi Kumar, PhD, Oncology Scientist/Senior Medical Writer, has disclosed no relevant financial relationships.

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 11 Number 7 | July 2013

**PRINCIPLES OF HER2 TESTING**

Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2A:** Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

**Category 2B:** Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

**Category 3:** Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Overview

Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The American Cancer Society estimates that 234,580 Americans will be diagnosed with breast cancer and 40,030 will die of the disease in the United States in 2013. The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer include up-to-date guidelines for the clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and breast cancer during in pregnancy (to view the complete and most recent version of these guidelines, visit NCCN.org). These NCCN Guidelines Insights highlight the important updates/changes specific to the management of HER2-positive metastatic breast cancer in the 2013 version of...
HER2-Targeted Therapy for Stage IV or Recurrent Metastatic Disease

HER2 is a proto-oncogene located on chromosome 17 and is amplified in 15% to 20% of breast carcinomas. Before the approval of trastuzumab, amplification of HER2 was considered a poor prognostic factor in patients with metastatic breast cancer. With the introduction of trastuzumab, the outcomes of patients with HER2-positive metastatic breast cancer dramatically improved. However, in most of these patients, the disease ultimately develops resistance to trastuzumab; therefore, effective targeted therapies are needed. In an attempt to further improve the outcomes of these patients, newer drugs targeting the HER2 pathway, including lapatinib, pertuzumab, and ado-trastuzumab (T-DM1), have been developed and added to the current standard of care.

HER2 Testing

Adequate standardization and validation of HER2 assays used in clinical practice is a concern, and data suggest that false-positive determinations are common. The NCCN Breast Cancer Panel endorses the ASCO/College of American Pathologists recommendations for quality control performance of HER2 testing and interpretation of results. The panel recommends that HER2 testing be performed only in laboratories accredited to perform such testing.

Either the immunohistochemistry (IHC) with the anti-HER2 antibodies or in situ hybridization (ISH) assay can be used to make an initial assessment of HER2 status. The NCCN Breast Cancer...
Panel recommends selecting patients for HER2-targeted therapy if their tumors are positive for HER2 by either ISH or IHC. The NCCN Guidelines consider IHC 3+ and HER2 gene/chromosome 17 ratio of 2 or greater as HER2-positive. According to the guidelines, borderline IHC samples (eg, IHC 2+) should be subjected to reflex testing by a validated complementary method, such as ISH, that has shown at least 95% concordance between IHC 0, 1+ results and ISH nonamplified results, and immunohistochemistry 3+ results and ISH amplified results. Also, it is recommended that borderline ISH results (average HER2/chromosome 17 ratio of 1.8 to <2 or average HER2 gene copy number >4 to <6) should undergo counting of additional cells, retesting by ISH, or reflex testing by a validated immunohistochemistry method (see BINV-A, page 755).

**Pertuzumab**

Pertuzumab is a recombinant humanized monoclonal antibody that inhibits the ligand-dependent dimerization of HER2 and its downstream signaling. Pertuzumab and trastuzumab bind to different epitopes of the HER2 receptor and have complementary mechanisms of action. Therefore, the rationale for administering the drugs together is to achieve a more powerful blockage of the HER2 pathway. This was demonstrated to be true in tumor models and in humans, wherein combining pertuzumab with trastuzumab provided a greater overall antitumor effect than either alone.^[8,9^]

In a randomized, double-blind, phase III study (CLEOPATRA), 808 women with HER2-positive metastatic breast cancer were randomized to receive trastuzumab and docetaxel with or without pertuzumab as their first-line treatment.^[10^] The results demonstrated a 6.1-month improvement in median progression-free survival with the addition of pertuzumab (12.4 vs 18.5 months; hazard ratio [HR] for progression or death, 0.62; 95% CI, 0.51–0.75; \( P < .001 \)). In addition, a strong trend was seen toward
DOsing Schedules for Chemotherapy Regimens for Her-2 Positive Recurrent or Metastatic Breast Cancer

Preferred First-Line Agents for Her2-Positive Disease:
- Pertuzumab + trastuzumab + docetaxel
- Pertuzumab 840 mg IV day 1 followed by 420 mg IV
- Trastuzumab 8 mg/kg IV day 1 followed by 6 mg/kg IV
- Docetaxel 75-100 mg/m² IV day 1
  Cycled every 21 days.

Pertuzumab + trastuzumab + weekly paclitaxel
- Pertuzumab 840 mg IV day 1 followed by 420 mg IV every 21 days
- Trastuzumab
  - 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly
  - 8 mg/kg IV day 1 followed by 6 mg/kg IV every 21 days
- Paclitaxel 80 mg/m² IV day 1 weekly.

Other First-Line Agents for Her2-Positive Disease:
- TCH chemotherapy
  - Carboplatin AUC 6 IV day 1
  - Paclitaxel 175 mg/m² IV day 1
  Cycled every 21 days.
  - Trastuzumab
    - 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly
    - 8 mg/kg IV day 1 followed by 6 mg/kg IV every 21 days
- Weekly TCH chemotherapy
  - Paclitaxel 80 mg/m² IV days 1, 8, & 15
  - Carboplatin AUC 2 IV days 1, 8, & 15
  Cycled every 28 days.
  - Trastuzumab
    - 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly
    - 8 mg/kg IV day 1 followed by 6 mg/kg IV every 21 days

Trastuzumab + Paclitaxel
- Paclitaxel 175 mg/m² IV day 1 cycled every 21 days
- 80-100 mg/m² IV day 1 cycled every 21 days
- 35 mg/m² IV days 1, 8, and 15

Trastuzumab + Docetaxel
- Docetaxel
  - 80-100 mg/m² IV day 1 cycled every 21 days
  - 35 mg/m² IV days 1, 8, and 15

Trastuzumab + Vinorelbine
- Vinorelbine 25 mg/m² IV day 1 weekly

Trastuzumab + Capecitabine
- Capecitabine 1000-1250 mg/m² PO twice daily days 1-14
  Cycled every 21 days.
  - Trastuzumab
    - 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly
    - 8 mg/kg IV day 1 followed by 6 mg/kg IV every 21 days

An overall survival benefit with pertuzumab, with a 34% reduction in the risk of death (HR, 0.66; 95% CI, 0.52–0.84; \( P = .0008 \)). The median overall survival was 37.6 months in the nonpertuzumab group and had not yet been reached at the time of analysis in the group treated with pertuzumab. Notably, no significant difference was seen in health-related quality of life or toxicities between the treatment arms, including no increase in either symptomatic or asymptomatic cardiac dysfunction.

Phase II trials have also assessed the activity and tolerability for pertuzumab, pertuzumab with trastuzumab, and other regimens combining pertuzumab and trastuzumab together with other active cytotoxics, such as paclitaxel and vinorelbine (Clinical-Trials.gov identifier: NCT01276041). Phase III trials of pertuzumab plus chemotherapy without trastuzumab have not been reported.

Pertuzumab has antitumor activity in patients beyond the first-line setting. The results of a multicenter, open-label, single-arm, phase II study show that the combination of pertuzumab and trastuzumab is active and well tolerated in patients with HER2-positive metastatic breast cancer that has progressed on prior trastuzumab therapy. The trial reported an objective response rate of 24.2% and a clinical benefit rate of 50%. To determine whether the clinical benefit seen in the study was from pertuzumab alone or was a result of the combined effect of pertuzumab and trastuzumab, a cohort of 29 patients whose disease progressed during prior trastuzumab-based therapy received pertuzumab monotherapy until progressive disease or unacceptable toxicity. Of these, 17 patients with disease progression continued to receive pertuzumab with the addition of trastuzumab. In the 29 patients who received pertuzumab monotherapy, the objective response and clinical benefit rates reported were 3.4% and 10.3%, respectively, whereas in the 17 patients who received dual blockade after progression on pertuzumab, the objective response rate and clinical benefit rate were 17.6% and 41.2%, respectively.
Further research is expected to determine the ideal sequencing strategy for anti-HER2 therapy.

**NCCN Recommendations:** Based on the available data, the NCCN Breast Cancer Panel recommends pertuzumab plus trastuzumab in combination with a taxane as a preferred option for first-line treatment of patients with HER2-positive metastatic breast cancer (see BINV-21, page 756). Pertuzumab plus trastuzumab in combination with docetaxel is a category 1 recommendation, and in combination with paclitaxel is a category 2A recommendation (see BINV-O 4 of 7, page 758, for dosing schedule).

For patients with disease progression after treatment with trastuzumab-based therapy without pertuzumab, the NCCN Breast Cancer Panel recommends considering a line of therapy containing both trastuzumab plus pertuzumab with or without a cytotoxic agent (eg, vinorelbine or taxane; see BINV-21, page 756).

**T-DM1**
T-DM1 is a first-in-class antibody–drug conjugate. Through a stable linker, the HER-2 targeting antitumor portion of trastuzumab is conjugated with the microtubule-inhibitory agent DM1 (derivative of maytansine). Therefore, T-DM1 delivers its antitumor activity to HER2-overexpressing cells through combining the specificity of trastuzumab with cytotoxicity of maytansine, thus increasing the therapeutic index.18

A recent randomized, multicenter, open-label, phase III study (EMILIA) showed overall and progression-free survival benefits for T-DM1 compared with the combination of lapatinib and capecitabine in patients with HER2-positive or metastatic breast cancer previously treated with a taxane-trastuzumab regimen.19 The median progression-free survival (assessed by independent review) with T-DM1 was 9.6 months versus 6.4 months with lapatinib plus capecitabine; the HR for progression or death from any cause was 0.65 (95% CI, 0.55–0.77; P<.001). The

---

**DOSING SCHEDULES FOR CHEMOTHERAPY REGIMENS FOR HER-2 POSITIVE RECURRENT OR METASTATIC BREAST CANCER**

**Preferred agents for trastuzumab-exposed HER2-positive disease:**

Ado-trastuzumab emtansine (T-DM1)22
- 3.6 mg/kg IV day 1
- Cycled every 21 days.

**Other agents for trastuzumab-exposed HER2-positive disease:**

Lapatinib + capecitabine42
- Lapatinib 1250 mg PO daily days 1-21
- Capecitabine 1000 mg/m² PO twice daily days 1-14
- Cycled every 21 days.

Trastuzumab + capecitabine43
- Capecitabine 1000-1250 mg/m² PO twice daily days 1-14
- Cycled every 21 days.
  - Trastuzumab
    - 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly35,41
    - or
    - 8 mg/kg IV day 1 followed by 6 mg/kg IV every 21 days33

Trastuzumab + lapatinib44
- Lapatinib 1000 mg PO daily
- Cycled every 21 days.
  - Trastuzumab
    - 4 mg/kg IV day 1 followed by 2 mg/kg IV weekly
    - or
    - 8 mg/kg IV day 1 followed by 6 mg/kg IV every 21 days33

See References (BINV-O, 6 of 7)
stratified HR for death from any cause with T-DM1 versus lapatinib plus capecitabine was 0.62 (95% CI, 0.48–0.81; \( P = .0005 \)). Rates of grade 3 or 4 adverse events were higher with lapatinib plus capecitabine than with T-DM1 (57% vs 41%). The incidences of thrombocytopenia and increased serum aminotransferase levels were higher with T-DM1 (frequency >25%), whereas the incidences of diarrhea, nausea, vomiting, and palmar-plantar erythrodysesthesia were higher with lapatinib plus capecitabine.\(^{19}\)

**NCCN Recommendations**: Based on the available data, the NCCN Breast Cancer Panel recommends T-DM1 as a preferred option for treatment of patients with HER2-positive metastatic breast cancer who were previously treated with a trastuzumab-based regimen (see BINV-21, page 756, and BINV-O 5 of 7, page 759, for dosing schedule).

**Conclusions**

The NCCN Guidelines for Breast Cancer are in continuous evolution. They are updated annually or sometimes more often, if new high-quality clinical data become available in the interim. The recommendations in the NCCN Guidelines, with few exceptions, are based on the evidence from clinical trials. Expert medical clinical judgment is required to apply these guidelines in the context of an individual patient to provide optimal care. The physician and the patient have the responsibility to jointly explore and select the most appropriate option from among the available alternatives. When possible, consistent with NCCN philosophy, the NCCN Breast Cancer Panel strongly encourages patient/physician participation in prospective clinical trials. The full version of the 2013 NCCN Guidelines for Breast Cancer is available online (NCCN.org).

**References**

Instructions for Completion

To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 70% minimum passing score and complete the evaluation at http://education.nccn.org/node/24674; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet.

Posttest Questions

1. True or False: The NCCN Guidelines consider IHC score of 3+ and HER2 gene/chromosome 17 ratio ≥2 as HER2-positive.
2. For a woman who has been newly diagnosed with HER2-positive, ER/PR-negative metastatic breast cancer, which of the following treatment options is listed as category 1 in the current NCCN Guidelines?
   a. Pertuzumab plus trastuzumab in combination with paclitaxel
   b. Pertuzumab plus trastuzumab in combination with docetaxel
   c. Trastuzumab with or without chemotherapy
d. a and b
e. All of the above
3. A 55-year-old woman with HER2-positive breast cancer treated with trastuzumab and paclitaxel has clear progression of the disease with documented metastases to the lungs, liver, and bones. According to the NCCN Guidelines, which of the following is a preferred treatment option for this individual?
   a. Ado-trastuzumab emtansine (T-DM1)
   b. Trastuzumab + laptinib
c. Trastuzumab + pertuzumab